Fourpath Capital Management LLC Has $5.06 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fourpath Capital Management LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 2.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,733 shares of the medical research company’s stock after selling 207 shares during the quarter. Fourpath Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $5,063,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in TMO. AMF Tjanstepension AB bought a new position in Thermo Fisher Scientific in the third quarter valued at approximately $42,409,000. Czech National Bank raised its holdings in shares of Thermo Fisher Scientific by 7.0% during the 3rd quarter. Czech National Bank now owns 77,816 shares of the medical research company’s stock worth $48,135,000 after buying an additional 5,076 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Thermo Fisher Scientific by 29.8% during the 3rd quarter. GAMMA Investing LLC now owns 4,851 shares of the medical research company’s stock worth $3,001,000 after buying an additional 1,115 shares during the last quarter. Diversified Trust Co grew its position in Thermo Fisher Scientific by 7.6% in the third quarter. Diversified Trust Co now owns 10,190 shares of the medical research company’s stock valued at $6,303,000 after acquiring an additional 717 shares during the last quarter. Finally, Chemistry Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 8.9% in the third quarter. Chemistry Wealth Management LLC now owns 587 shares of the medical research company’s stock worth $363,000 after acquiring an additional 48 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 9,000 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the transaction, the chief executive officer now owns 14,608 shares in the company, valued at $8,076,178.88. The trade was a 38.12 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 29,000 shares of company stock valued at $15,859,540 in the last three months. 0.34% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Bernstein Bank upped their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Morgan Stanley upped their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. TD Cowen upped their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Finally, Citigroup lifted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a research note on Friday. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $658.00.

Check Out Our Latest Analysis on TMO

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $593.38 on Tuesday. The stock has a market cap of $226.97 billion, a P/E ratio of 35.90, a P/E/G ratio of 4.06 and a beta of 0.77. The business’s fifty day moving average is $541.37 and its 200 day moving average is $571.18. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.29 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is currently 9.44%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.